That vaccine is currently in stage two clinical trials. It's still a going concern. We're very excited about those opportunities, not just for COVID but also for the delivery of many other vaccines for respiratory infections going forward. That intellectual property and that strategy are still here with us at McMaster. We're excited about it.
With respect to some of the other challenges in making drugs, the short answer is that drug discovery is very hard and can fall apart in many ways. In discoveries that we've made, getting them down towards additional development is where you start to realize unexpected toxicological issues. This is why drug discovery is so expensive. It takes a lot of money, and it's not terribly exciting discovery science that students want to do. It's very careful analysis going forward, and that's one of the challenges that we have here.
In our case, a lot of that was funded by the NIH in the United States, not CIHR. For the current drug candidate that we're trying to move forward, we're looking mostly to Europe to get funding for that, but we're also being supported by the NIH right now.
CIHR funded the initial discovery, but once that discovery has been funded, there's really no mechanism in Canada to move these things forward so that we become attractive to, say, Dr. Outterson's CARB-X.